The New York State Office for the Aging announced Wednesday that it is partnering with Intuition Robotics to bring an AI robotic care companion into the homes of 800 older adults as part of the state's efforts to battle social isolation and support aging in place.
Webinar Date: June 7, 2022 Time: 3:30pm ET / 12:30pm PT
In the next five years, healthcare and life sciences organizations will be navigating unique, disruptive forces presented by a digital-first world that will shape many aspects of the industry landscape from value-based care to prescription digital therapeutics. A report from IDC Research, a premier global market research company, offers some predictions on how organizations can navigate the winds of change impacting what technologies to adopt, capabilities to advance, and partnerships to pursue.
The recent IDC FutureScape: Worldwide Healthcare Industry 2022 Predictions moving healthcare and life sciences organizations forward in a digital-first world
The role innovative and disruptive technologies will play in helping healthcare become more connected and personalized
Top business and IT considerations for organizations as the industry continues to digitally transform
MedCity News is inviting all startups aiming to reinvent the clinical trials industry to apply to take part in the pitch contest during INVEST PharmaTechon July 26.
Startups in this category are developing products – both technology and services – that can help transform in-person, site-based clinical trials into purely clinical trials or incorporate additional digital elements to traditional clinical trial processes.
The contest is open to any startup founded in 2020 and earlier.
By Dr. Eric Gantwerker Wednesday, May 25, 2022 5:47 PM
It's time for the industry to invest more in software-based solutions, providing healthcare professionals the resources they need to thrive in an increasingly digitized field. Otherwise, they will be behind the curve of medical advances, playing catch-up with their future-minded peers.
A clinical hold on an Antios Therapeutics drug has led to the end of a collaboration with Assembly Biosciences less than a year after their alliance began. The partners had hoped pairing their drugs with an approved Gilead Sciences antiviral would produce a combination hepatitis B treatment with the potential for a cure.
While a jury agreed that an insurance company breeched a good faith contract by not covering proton beam therapy, not all agree that the treatment modality actually improves outcomes for cancer patients.
Today, the pharmaceutical industry is undergoing a rapid and dynamic transformation. Successful contract management plays an instrumental role in navigating this landscape.
No comments